🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ADA2023 📍Cardiorenal Effectiveness of Empagliflozin vs GLP1ra in Advanced #CKD (stage 3 & 4) – Results from the EMPRISE Study 📍large🇺🇸new user cohort study 👉Empa vs GLP1 treatmentassoc: ⤵️🏥💔 (32%RRR) ⤵️ESRD (30%RRR) ↔️MACE ↔️☠️ Muthu Vaduganathan Shelley Zieroth

Dual incretin debate‼️ #ADA2023 🔹Fascinating discussions on cost effectiveness and benefits 🔸Regardless, costs need to come down 🔹 Generic GLP-1 might supper use? 🔸Longterm implications of not treating effectively 🤔 🔹 Multimodal - not just medications 🔸Not just

Cumulative probability of micro-NFPA growth was 7.8% and 14.5% at 3 and 5 years, respectively. Only one patient was offered surgery during the first three years of monitoring (due to tumour growth rather than impact on the optic pathways).

Omics analyses take center stage this am #ADA2023 Julie B. Sneddon UCSF School of Medicine Inês Cebola Imperial College London & @ccrobertson01 NIH #ADA2023 Ballroom 6DE #islets #RNAseq #diabetes #T2D #T1D

Up front & free to read in our Jul issue #editorspicks: Effects of postprandial exercise on blood glucose levels in adults with type 1 diabetes: a review bit.ly/43rDpBm

An overview of the new data #obesity #T2D for GLP-1-based medicines, from oral small molecule GLP-1RA, to higher dose oral #Semaglutide to Cagri-Sema and Triple G retatrutide via Nature News & Views @saimamaysidik The future is bright nature.com/articles/d4158…

The latest glucagon review Diabetologia Nicolai J. Wewer Albrechtsen #diabetes #obesity link.springer.com/article/10.100…

Tremendous progress in melanocortin receptor-based therapeutics, a new review from the experts #obesity Nature Reviews Endocrinology nature.com/articles/s4157…

Amazing work by the fab Claire Davies Dr Becky Haines UKCPA Diabetes & Endocrinology Committee Hannah Beba Robin Conibere DSNforumUK Dr Dave Triska Selvaseelan Selvarajah GoggleDocs 🙏🏻share

How to differentiate the new emerging GLP-1-based medicines beyond A1c and #weightloss #ADA2023 For some drugs, there may be an opportunity in reducing the number of steps needed to achieve maximally effective medicines, simplifying implementation for PPL and HCPs #T2D #obesity

RhoGDIα is a clinically relevant controller of skeletal muscle #insulin sensitivity and whole-body glucose homeostasis, mechanistically by modulating Rac1 activity PNASNews pnas.org/doi/10.1073/pn…

#Cancer metabolism. A hyperglycemic state substantially enhances the efficacy of conventional single- and multi-agent chemotherapy regimens against PDAC via reduced glutamate-cysteine ligase catalytic subunit #PancreaticCancer nature.com/articles/s4146…

As the gut #microbiome translational tsunami continues, there are still enormous opportunities to describe the fungus among us. Don’t be that loser left behind doing simple reductionist mechanistic gut physiology without the #microbiota Nature Reviews Gastroenterology & Hepatology nature.com/articles/s4157…

Verapamil might be the real deal for delay of type 1 #diabetes #T1D more trials underway. Some new mechanistic insights here Diabetes, a research journal of the ADA 🧪 diabetesjournals.org/diabetes/artic…

This is fun!

Who is overseeing contract in between NRS Healthcare and #NHS? An order for the same day delivery of a hoist for a high clinical risk patient accepted, 8 phone calls since noon, nobody accepting responsibility. No delivery or a plan. BBC Health News The Guardian nope s

After a strong start, competition for Novo Nordisk Eli Lilly and Company is coming in the #weightloss space, with widespread innovation to bring options for more people @amgen Roche Altimmune, Inc. Structure Therapeutics Viking Therapeutics Pfizer Inc. Boehringer Ingelheim economist.com/business/2024/… The Economist

SGLT2i reduce the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease The journey started as a glucose lowering drug! academic.oup.com/eurheartj/adva…

Do you remember when you joined X? I do! #MyXAnniversary It has been a journey…